Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy.

IF 2.8 3区 医学 Q3 ONCOLOGY
Mahito Atsuta, Fumihiko Urabe, Kosuke Iwatani, Masataka Kubo, Naoki Uchida, Hirokazu Kagawa, Naoya Tomomasa, Shun Saito, Takayuki Sano, Wataru Fukuokaya, Kazuhiro Takahashi, Takafumi Yanagisawa, Shunsuke Tsuzuki, Takahiro Kimura, Jun Miki
{"title":"Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy.","authors":"Mahito Atsuta, Fumihiko Urabe, Kosuke Iwatani, Masataka Kubo, Naoki Uchida, Hirokazu Kagawa, Naoya Tomomasa, Shun Saito, Takayuki Sano, Wataru Fukuokaya, Kazuhiro Takahashi, Takafumi Yanagisawa, Shunsuke Tsuzuki, Takahiro Kimura, Jun Miki","doi":"10.1007/s10147-025-02791-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Assessing the quality of surgical procedures is crucial for improving outcomes in radical cystectomy (RC). While the Pentafecta metric has been used, its reliance on the absence of local recurrence within 1 year delays postoperative assessment. For timely clinical decision-making, a new metric that facilitates earlier evaluation is needed. We propose such a metric, named \"Trifecta\". We evaluated its impact on prognosis and identified predictors for achieving it.</p><p><strong>Methods: </strong>The \"Trifecta\" metric was defined as meeting three criteria: adequate lymphadenectomy (≥ 10 nodes), negative surgical margins, and absence of Clavien-Dindo grade 3-5 complications within 30 days after surgery. This retrospective study analyzed data from patients who underwent RC and lymphadenectomy between April 2014 and June 2024. Kaplan-Meier analysis and Cox proportional hazards models were used to assess oncological outcomes, while logistic regression was used to identify predictors for failing to achieve \"Trifecta\" .</p><p><strong>Results: </strong>Of the 196 patients included, 121 (61.7%) achieved \"Trifecta\" and this was significantly associated with improved intrapelvic RFS (HR 0.42; P = 0.014), CSS (HR 0.56; P = 0.032), and OS (HR 0.57; P = 0.020) but not MFS (HR 0.85; P = 0.620). Low serum levels of albumin were significantly associated with \"Trifecta\" failure (OR 2.06; P = 0.021), but not with survival outcomes.</p><p><strong>Conclusion: </strong>Achieving \"Trifecta\" was associated with improved survival outcomes, and low serum levels of albumin predicted a higher likelihood of failure to achieve it. The \"Trifecta\" metric enables early and clinically relevant evaluation of surgical quality, offering a practical alternative to traditional metrics.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1832-1840"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02791-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Assessing the quality of surgical procedures is crucial for improving outcomes in radical cystectomy (RC). While the Pentafecta metric has been used, its reliance on the absence of local recurrence within 1 year delays postoperative assessment. For timely clinical decision-making, a new metric that facilitates earlier evaluation is needed. We propose such a metric, named "Trifecta". We evaluated its impact on prognosis and identified predictors for achieving it.

Methods: The "Trifecta" metric was defined as meeting three criteria: adequate lymphadenectomy (≥ 10 nodes), negative surgical margins, and absence of Clavien-Dindo grade 3-5 complications within 30 days after surgery. This retrospective study analyzed data from patients who underwent RC and lymphadenectomy between April 2014 and June 2024. Kaplan-Meier analysis and Cox proportional hazards models were used to assess oncological outcomes, while logistic regression was used to identify predictors for failing to achieve "Trifecta" .

Results: Of the 196 patients included, 121 (61.7%) achieved "Trifecta" and this was significantly associated with improved intrapelvic RFS (HR 0.42; P = 0.014), CSS (HR 0.56; P = 0.032), and OS (HR 0.57; P = 0.020) but not MFS (HR 0.85; P = 0.620). Low serum levels of albumin were significantly associated with "Trifecta" failure (OR 2.06; P = 0.021), but not with survival outcomes.

Conclusion: Achieving "Trifecta" was associated with improved survival outcomes, and low serum levels of albumin predicted a higher likelihood of failure to achieve it. The "Trifecta" metric enables early and clinically relevant evaluation of surgical quality, offering a practical alternative to traditional metrics.

根治性膀胱切除术围手术期质量评估新指标三分法的临床应用。
背景:评估手术质量对于改善根治性膀胱切除术(RC)的预后至关重要。虽然使用了Pentafecta指标,但其对1年内局部复发的依赖延迟了术后评估。为了及时做出临床决策,需要一种便于早期评估的新指标。我们提出这样一个度量标准,命名为“Trifecta”。我们评估了其对预后的影响,并确定了实现预后的预测因素。方法:“三联”指标被定义为满足三个标准:充分的淋巴结切除(≥10个淋巴结),阴性手术切缘,术后30天内无Clavien-Dindo 3-5级并发症。这项回顾性研究分析了2014年4月至2024年6月期间接受RC和淋巴结切除术的患者的数据。Kaplan-Meier分析和Cox比例风险模型用于评估肿瘤预后,而逻辑回归用于确定未能实现“三联曲”的预测因素。结果:纳入的196例患者中,121例(61.7%)实现了“三联曲”,这与改善的盆腔内RFS显著相关(HR 0.42;P = 0.014), CSS (hr 0.56;P = 0.032), OS (HR 0.57;P = 0.020),但无MFS (HR 0.85;p = 0.620)。低血清白蛋白水平与“三联曲”失败显著相关(OR 2.06;P = 0.021),但与生存结局无关。结论:实现“三连效”与改善生存结果相关,低血清白蛋白水平预示着更高的失败可能性。“Trifecta”指标能够对手术质量进行早期和临床相关的评估,为传统指标提供了一种实用的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信